KPL-387 + Placebo
Phase 2/3Recruiting 0 watching 0 views this week📈 Rising
60
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pericarditis
Conditions
Pericarditis, Pericarditis Acute, Recurrent Pericarditis
Trial Timeline
Jul 25, 2025 → Dec 31, 2029
NCT ID
NCT07010159About KPL-387 + Placebo
KPL-387 + Placebo is a phase 2/3 stage product being developed by Kiniksa Pharmaceuticals for Pericarditis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07010159. Target conditions include Pericarditis, Pericarditis Acute, Recurrent Pericarditis.
Hype Score Breakdown
Clinical
22
Activity
15
Company
5
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07010159 | Phase 2/3 | Recruiting |
Competing Products
3 competing products in Pericarditis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KPL-914 | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| KPL-387 | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| Rilonacept + Placebo | Kiniksa Pharmaceuticals | Phase 3 | 72 |